VivoSeq
Other

Intraoperative

0

Pipeline Programs

22

Active Trials

1

Companies Involved

Intraoperative is an early-stage landscape with 0 programs across 1 company. The most active players are SURGE Therapeutics.

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

25/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

7/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

118

clinical trials

Completed66 · 56%
Unknown status22 · 19%
Recruiting14 · 12%
Terminated6 · 5%
Not yet recruiting6 · 5%
Active, not recruiting2 · 2%
Other2 · 2%

Trial Activity

118 trials

TumorGlow Intraoperative Molecular Imaging (IMI)
Recruiting·UUniversity of Pennsylvania·Phase 1/2·NCT04723810·500 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)